Nanobiotix Study News Today

Regional activation for Nanobiotix pivotal Phase 3 trial in head and neck cancer proceeds as planned with first patient enrolled in Asia by partner LianBioThe collaboration continues to build momentum behind LianBio’s leadership in Asia while Nanobiotix remains focused on enrollment globallyPARIS & CAMBRIDGE, Mass....

Regional activation for Nanobiotix pivotal Phase 3 trial in head and neck cancer proceeds as planned with first patient enrolled in Asia by partner LianBio The collaboration continues to build

NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer - read this article along with other careers information, tips and advice on BioSpace

First patient randomized in pivotal phase III study evaluating radiotherapy-activated NBTXR3 with or without cetuximab in high-risk elderly patients with locally advanced head and neck squamous

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021 Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study eval...